The popularity of Sildenafil initially drove a period of growth for pharma, however recent shifts present a complicated outlook for shareholders. Generic alternatives are eating into earnings, and persistent patent https://marviniyop394346.ja-blog.com/41480174/viagra-and-the-pharmaceutical-industry-a-volatile-bet